Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401293 · ClinicalTrials.gov registry record · Phase 3
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
A Phase 3 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 257
- Enrollment target
NCT04401293 is a Phase 3 study that has completed, run by Northwell Health. The registered enrollment target is 257 participants.
The verdict
NCT04401293, a Phase 3 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 257 participants
- Enrollment target
Study Summary
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH
Interventions
- DRUG Enoxaparin
- DRUG Prophylactic/Intermediate Dose Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2020-04-26 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401293
The ClinicalTrials.gov registry entry for NCT04401293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT04401293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04401293 about?
NCT04401293 is a clinical study titled "Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients". The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediat...
What is the current status of trial NCT04401293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 257 participants. The study started on 2020-04-26. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT04401293?
The interventions under investigation include: Enoxaparin (DRUG), Prophylactic/Intermediate Dose Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT04401293?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.